Haemonetics Corp (HAE)

$73.80 -0.97 (-1.30%)
Market Cap 3.59B
Revenue (ttm) 1.36B
Net Income (ttm) 167.68M
EPS (ttm) N/A
PE Ratio 16.06
Forward PE 15.00
Profit Margin 12.32%
Debt to Equity Ratio 1.12
Volume 1,007,900
Avg Vol 551,964
Day's Range N/A - N/A
Shares Out 48.04M
Stochastic %K 74%
Beta 0.36
Analysts Strong Sell
Price Target $91.82

Company Profile

Haemonetics Corporation, a medical technology company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk D...

Industry: Medical Devices
Sector: Healthcare
Phone: 781 848 7100
Address:
125 Summer Street, Boston, United States
JarvisFlow
JarvisFlow Jun. 26 at 1:00 PM
Baird has updated their rating for Haemonetics ( $HAE ) to Outperform with a price target of 87.
0 · Reply
Estimize
Estimize May. 26 at 7:04 PM
Wall St is expecting 1.01 EPS for $HAE Q1 [Reporting 08/12 BMO] http://www.estimize.com/intro/hae?chart=historical&metric_name=eps&utm_cont
0 · Reply
d_risk
d_risk May. 22 at 3:03 PM
$HAE - Haemonetics Corporation Common Stock - 10K - Updated Risk Factors HAE’s 2025 10-K risk factors spotlight Plasma and Hospital as growth drivers amid Blood Center challenges, heightened customer concentration risks, new acquisition and AI integration risks, expanded regulatory scrutiny including global tax and ESG pressures, supply chain vulnerabilities, evolving healthcare market dynamics, and a $500M share repurchase program—all amid intensified geopolitical and pandemic uncertainties. #Healthcare #ShareRepurchase #ESG #AIIntegration #GeopoliticalRisk #SupplyChain #RegulatoryScrutiny #CustomerConcentration #HospitalGrowth #Plasma 🟢 Added 🟠 Removed https://d-risk.ai/HAE/10-K/2025-05-21
0 · Reply
JarvisFlow
JarvisFlow May. 20 at 1:02 PM
JMP Securities has updated their rating for Haemonetics ( $HAE ) to Market Outperform with a price target of 100.
0 · Reply
Estimize
Estimize May. 19 at 2:03 PM
Wall St is expecting 1.01 EPS for $HAE Q1 [Reporting 08/12 BMO] http://www.estimize.com/intro/hae?chart=historical&metric_name=eps&utm_cont
0 · Reply
JarvisFlow
JarvisFlow May. 8 at 6:53 PM
Needham has updated their rating for Haemonetics ( $HAE ) to Buy with a price target of 84.
0 · Reply
Rdg57
Rdg57 May. 8 at 2:27 PM
$HAE $100 eoy
0 · Reply
ZacksResearch
ZacksResearch May. 1 at 1:38 PM
4 MedTech names that could crush Q1 earnings? Here's the shortlist 🔍 $HIMS, $GMED, $QDEL, and $HAE all show bullish setups heading into reports — each with a Zacks Rank of #2 or #3 and a positive Earnings ESP 📊 ➡️ HIMS leads the charge with a massive +115.69% Earnings ESP and 180% YoY EPS growth forecast ➡️ QDEL isn’t far behind with a +10% ESP and 36.4% projected EPS growth ➡️ GMED & HAE also flash upside potential with strong beat histories and solid year-over-year gains Find out what could drive these names to beat expectations 👉 https://www.zacks.com/commentary/2459869/4-medtech-stocks-poised-to-outshine-q1-earnings-estimates?cid=sm-stocktwits-2-2459869-body&ADID=SYND_STOCKTWITS_TWEET_2_2459869_BODY
0 · Reply
swingingtech
swingingtech Apr. 3 at 3:09 AM
$HAE $HD $ELF https://wallstreetwaves.com/key-wednesday-options-movements-hae-hd-elf-insights/
0 · Reply
Estimize
Estimize Mar. 31 at 2:00 PM
Wall St is expecting 1.22 EPS for $HAE Q4 [Reporting 05/13 BMO] http://www.estimize.com/intro/hae?chart=historical&metric_name=eps&utm_cont
0 · Reply
Latest News on HAE
Haemonetics to Present at Goldman Sachs 46th Annual Global Healthcare Conference

May 30, 2025, 6:00 AM EDT - 4 weeks ago

Haemonetics to Present at Goldman Sachs 46th Annual Global Healthcare Conference

Haemonetics Corporation (HAE) Q4 2025 Earnings Call Transcript

May 10, 2025, 1:05 PM EDT - 6 weeks ago

Haemonetics Corporation (HAE) Q4 2025 Earnings Call Transcript

Haemonetics 4th Quarter and Fiscal Year 2025 Earnings Release Available on Investor Relations Website

May 8, 2025, 6:00 AM EDT - 7 weeks ago

Haemonetics 4th Quarter and Fiscal Year 2025 Earnings Release Available on Investor Relations Website

Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2025 Results: May 8, 2025

Mar 31, 2025, 4:00 PM EDT - 3 months ago

Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2025 Results: May 8, 2025

Haemonetics Announces Executive Leadership Updates

Mar 3, 2025, 4:10 PM EST - 4 months ago

Haemonetics Announces Executive Leadership Updates

Haemonetics to Present at Raymond James 46th Annual Institutional Investors Conference

Feb 24, 2025, 6:00 AM EST - 4 months ago

Haemonetics to Present at Raymond James 46th Annual Institutional Investors Conference

Haemonetics Corporation (HAE) Q3 2025 Earnings Call Transcript

Feb 6, 2025, 12:19 PM EST - 5 months ago

Haemonetics Corporation (HAE) Q3 2025 Earnings Call Transcript

Haemonetics 3rd Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website

Feb 6, 2025, 6:00 AM EST - 5 months ago

Haemonetics 3rd Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website

Haemonetics Completes Sale of Whole Blood Assets to GVS, S.p.A

Jan 14, 2025, 6:13 AM EST - 5 months ago

Haemonetics Completes Sale of Whole Blood Assets to GVS, S.p.A

Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2025 Results: February 6, 2025

Jan 8, 2025, 5:03 PM EST - 6 months ago

Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2025 Results: February 6, 2025

Haemonetics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 6:00 AM EST - 6 months ago

Haemonetics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Haemonetics Announces Sale of Whole Blood Assets to GVS, S.p.A

Dec 3, 2024, 1:16 AM EST - 7 months ago

Haemonetics Announces Sale of Whole Blood Assets to GVS, S.p.A

Haemonetics Corporation (HAE) Q2 2025 Earnings Call Transcript

Nov 9, 2024, 1:34 AM EST - 8 months ago

Haemonetics Corporation (HAE) Q2 2025 Earnings Call Transcript

Haemonetics 2nd Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website

Nov 7, 2024, 6:00 AM EST - 8 months ago

Haemonetics 2nd Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website

Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2025 Results: November 7, 2024

Oct 3, 2024, 4:05 PM EDT - 9 months ago

Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2025 Results: November 7, 2024

Top 3 Health Care Stocks That Are Set To Fly This Quarter

Aug 16, 2024, 7:57 AM EDT - 11 months ago

Top 3 Health Care Stocks That Are Set To Fly This Quarter

IBRX PGNY

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Aug 15, 2024, 6:30 AM EDT - 11 months ago

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics Corporation (HAE) Q1 2025 Earnings Call Transcript

Aug 8, 2024, 1:13 PM EDT - 11 months ago

Haemonetics Corporation (HAE) Q1 2025 Earnings Call Transcript

Haemonetics 1st Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website

Aug 8, 2024, 6:00 AM EDT - 11 months ago

Haemonetics 1st Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website

Haemonetics Announces CE Mark Certification for the SavvyWire® Pre-Shaped Pressure Guidewire

Jul 30, 2024, 6:00 AM EDT - 11 months ago

Haemonetics Announces CE Mark Certification for the SavvyWire® Pre-Shaped Pressure Guidewire

Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2025 Results: August 8, 2024

Jul 8, 2024, 4:05 PM EDT - 1 year ago

Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2025 Results: August 8, 2024

Haemonetics Undervalued As It Passes Into A Period Of Softer Reported Growth

Jun 21, 2024, 3:50 PM EDT - 1 year ago

Haemonetics Undervalued As It Passes Into A Period Of Softer Reported Growth

Haemonetics Launches Limited Market Release for New VASCADE MVP XL Vascular Closure Device

Jun 18, 2024, 4:15 PM EDT - 1 year ago

Haemonetics Launches Limited Market Release for New VASCADE MVP XL Vascular Closure Device

Haemonetics Prices Upsized Private Placement of $600 Million Convertible Senior Notes

May 23, 2024, 6:00 AM EDT - 1 year ago

Haemonetics Prices Upsized Private Placement of $600 Million Convertible Senior Notes

Haemonetics Announces Proposed Convertible Senior Notes Offering

May 21, 2024, 4:05 PM EDT - 1 year ago

Haemonetics Announces Proposed Convertible Senior Notes Offering

Haemonetics Corporation (HAE) Q4 2024 Earnings Call Transcript

May 10, 2024, 12:25 AM EDT - 1 year ago

Haemonetics Corporation (HAE) Q4 2024 Earnings Call Transcript

Haemonetics 4th Quarter and Fiscal Year 2024 Earnings Release Available on Investor Relations Website

May 9, 2024, 6:00 AM EDT - 1 year ago

Haemonetics 4th Quarter and Fiscal Year 2024 Earnings Release Available on Investor Relations Website

Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2024 Results: May 9, 2024

Apr 10, 2024, 4:58 PM EDT - 1 year ago

Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2024 Results: May 9, 2024

Haemonetics Receives FDA Clearance for New TEG® 6s Global Hemostasis - HN Cartridge

Apr 4, 2024, 6:30 AM EDT - 1 year ago

Haemonetics Receives FDA Clearance for New TEG® 6s Global Hemostasis - HN Cartridge

Haemonetics Corporation Completes Acquisition of Attune Medical

Apr 1, 2024, 8:00 AM EDT - 1 year ago

Haemonetics Corporation Completes Acquisition of Attune Medical

Haemonetics Announces Definitive Agreement to Acquire Attune Medical

Mar 5, 2024, 6:00 AM EST - 1 year ago

Haemonetics Announces Definitive Agreement to Acquire Attune Medical

Haemonetics to Present at Raymond James 45th Annual Institutional Investors Conference

Feb 21, 2024, 5:57 PM EST - 1 year ago

Haemonetics to Present at Raymond James 45th Annual Institutional Investors Conference

Haemonetics to Present at Citi's 2024 Unplugged Medtech and Life Sciences Access Day

Feb 21, 2024, 5:55 PM EST - 1 year ago

Haemonetics to Present at Citi's 2024 Unplugged Medtech and Life Sciences Access Day

Haemonetics Corporation (HAE) Q3 2024 Earnings Call Transcript

Feb 8, 2024, 12:24 PM EST - 1 year ago

Haemonetics Corporation (HAE) Q3 2024 Earnings Call Transcript

Haemonetics 3rd Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website

Feb 8, 2024, 6:00 AM EST - 1 year ago

Haemonetics 3rd Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website

Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2024 Results: February 8, 2024

Jan 11, 2024, 4:05 PM EST - 1 year ago

Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2024 Results: February 8, 2024

Haemonetics Corporation Completes Acquisition of OpSens Inc.

Dec 12, 2023, 6:00 AM EST - 1 year ago

Haemonetics Corporation Completes Acquisition of OpSens Inc.

Haemonetics to Present at 42nd Annual J.P. Morgan Healthcare Conference

Dec 7, 2023, 4:05 PM EST - 1 year ago

Haemonetics to Present at 42nd Annual J.P. Morgan Healthcare Conference

Haemonetics: Solid Performance Of This Blood Play

Nov 22, 2023, 6:15 AM EST - 1 year ago

Haemonetics: Solid Performance Of This Blood Play

Haemonetics Corporation (HAE) Q2 2024 Earnings Call Transcript

Nov 3, 2023, 6:21 PM EDT - 1 year ago

Haemonetics Corporation (HAE) Q2 2024 Earnings Call Transcript

Haemonetics 2nd Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website

Nov 2, 2023, 6:00 AM EDT - 1 year ago

Haemonetics 2nd Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website

Haemonetics Offers Relatively Rare Momentum In A Tough Medical Device Environment

Oct 13, 2023, 4:37 PM EDT - 1 year ago

Haemonetics Offers Relatively Rare Momentum In A Tough Medical Device Environment

Haemonetics Corporation Announces Definitive Agreement to Acquire OpSens, Inc.

Oct 10, 2023, 6:00 AM EDT - 1 year ago

Haemonetics Corporation Announces Definitive Agreement to Acquire OpSens, Inc.

Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2024 Results: November 2, 2023

Oct 5, 2023, 4:05 PM EDT - 1 year ago

Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2024 Results: November 2, 2023

Haemonetics Announces European Expansion for VASCADE® Vascular Closure System

Aug 29, 2023, 6:30 AM EDT - 1 year ago

Haemonetics Announces European Expansion for VASCADE® Vascular Closure System

Haemonetics Corporation (HAE) Q1 2024 Earnings Call Transcript

Aug 8, 2023, 11:43 AM EDT - 2 years ago

Haemonetics Corporation (HAE) Q1 2024 Earnings Call Transcript

Haemonetics 1st Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website

Aug 8, 2023, 6:00 AM EDT - 2 years ago

Haemonetics 1st Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website

Diane M. Bryant Joins Haemonetics' Board of Directors

Aug 7, 2023, 4:10 PM EDT - 2 years ago

Diane M. Bryant Joins Haemonetics' Board of Directors

Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2024 Results: August 8, 2023

Jul 10, 2023, 4:05 PM EDT - 2 years ago

Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2024 Results: August 8, 2023

Haemonetics Receives FDA Clearance for Enhancements to NexSys PCS® Plasma Collection System

Jun 22, 2023, 6:15 AM EDT - 2 years ago

Haemonetics Receives FDA Clearance for Enhancements to NexSys PCS® Plasma Collection System

JarvisFlow
JarvisFlow Jun. 26 at 1:00 PM
Baird has updated their rating for Haemonetics ( $HAE ) to Outperform with a price target of 87.
0 · Reply
Estimize
Estimize May. 26 at 7:04 PM
Wall St is expecting 1.01 EPS for $HAE Q1 [Reporting 08/12 BMO] http://www.estimize.com/intro/hae?chart=historical&metric_name=eps&utm_cont
0 · Reply
d_risk
d_risk May. 22 at 3:03 PM
$HAE - Haemonetics Corporation Common Stock - 10K - Updated Risk Factors HAE’s 2025 10-K risk factors spotlight Plasma and Hospital as growth drivers amid Blood Center challenges, heightened customer concentration risks, new acquisition and AI integration risks, expanded regulatory scrutiny including global tax and ESG pressures, supply chain vulnerabilities, evolving healthcare market dynamics, and a $500M share repurchase program—all amid intensified geopolitical and pandemic uncertainties. #Healthcare #ShareRepurchase #ESG #AIIntegration #GeopoliticalRisk #SupplyChain #RegulatoryScrutiny #CustomerConcentration #HospitalGrowth #Plasma 🟢 Added 🟠 Removed https://d-risk.ai/HAE/10-K/2025-05-21
0 · Reply
JarvisFlow
JarvisFlow May. 20 at 1:02 PM
JMP Securities has updated their rating for Haemonetics ( $HAE ) to Market Outperform with a price target of 100.
0 · Reply
Estimize
Estimize May. 19 at 2:03 PM
Wall St is expecting 1.01 EPS for $HAE Q1 [Reporting 08/12 BMO] http://www.estimize.com/intro/hae?chart=historical&metric_name=eps&utm_cont
0 · Reply
JarvisFlow
JarvisFlow May. 8 at 6:53 PM
Needham has updated their rating for Haemonetics ( $HAE ) to Buy with a price target of 84.
0 · Reply
Rdg57
Rdg57 May. 8 at 2:27 PM
$HAE $100 eoy
0 · Reply
ZacksResearch
ZacksResearch May. 1 at 1:38 PM
4 MedTech names that could crush Q1 earnings? Here's the shortlist 🔍 $HIMS, $GMED, $QDEL, and $HAE all show bullish setups heading into reports — each with a Zacks Rank of #2 or #3 and a positive Earnings ESP 📊 ➡️ HIMS leads the charge with a massive +115.69% Earnings ESP and 180% YoY EPS growth forecast ➡️ QDEL isn’t far behind with a +10% ESP and 36.4% projected EPS growth ➡️ GMED & HAE also flash upside potential with strong beat histories and solid year-over-year gains Find out what could drive these names to beat expectations 👉 https://www.zacks.com/commentary/2459869/4-medtech-stocks-poised-to-outshine-q1-earnings-estimates?cid=sm-stocktwits-2-2459869-body&ADID=SYND_STOCKTWITS_TWEET_2_2459869_BODY
0 · Reply
swingingtech
swingingtech Apr. 3 at 3:09 AM
$HAE $HD $ELF https://wallstreetwaves.com/key-wednesday-options-movements-hae-hd-elf-insights/
0 · Reply
Estimize
Estimize Mar. 31 at 2:00 PM
Wall St is expecting 1.22 EPS for $HAE Q4 [Reporting 05/13 BMO] http://www.estimize.com/intro/hae?chart=historical&metric_name=eps&utm_cont
0 · Reply
NVDAMillionaire
NVDAMillionaire Mar. 27 at 1:53 AM
$HAE Digging HAE's innovative med tech play. Hospital segment looking strong. Might add to position on next dip. thoughtful article: https://beyondspx.com/article/haemonetics-a-pioneer-in-medical-technology-driving-better-patient-outcomes
0 · Reply
JarvisFlow
JarvisFlow Mar. 18 at 11:00 AM
Needham has adjusted their stance on Haemonetics ( $HAE ), setting the rating to Buy with a target price of 108 → 104.
0 · Reply
jParkz
jParkz Feb. 24 at 9:30 PM
$HAE News Haemonetics to Present at Raymond James 46th Annual Institutional Investors Conference https://marketwirenews.com/news-releases/haemonetics-to-present-at-raymond-james-46th-annual--5120338425392535.html $HAE
0 · Reply
Rdg57
Rdg57 Feb. 12 at 10:55 PM
$HAE $90 by eoy
0 · Reply
stkmkt
stkmkt Feb. 12 at 6:35 PM
$EW 3 undervalued stocks $EW $EXAS $HAE
0 · Reply
anachartanalyst
anachartanalyst Feb. 7 at 5:02 PM
$HAE https://anachart.com/wp-content/uploads/ana_temp/1738947757_soc-img.jpg
0 · Reply
Estimize
Estimize Feb. 6 at 10:07 PM
$HAE reported 1.19 EPS and 348.54 revenue for Q3. http://www.estimize.com/intro/hae?chart=historical&metric_name=eps&utm_content=HAE&utm_me
0 · Reply
Cutlass
Cutlass Feb. 6 at 7:47 PM
$HAE Alert set to review at 58 - ⏰
0 · Reply
OpenOutcrier
OpenOutcrier Feb. 6 at 2:17 PM
$HAE (-7.6% pre) Haemonetics (NYSE:HAE) Misses Q4 Revenue Estimates https://finance.yahoo.com/news/haemonetics-nyse-hae-misses-q4-112824890.html
0 · Reply
DonCorleone77
DonCorleone77 Feb. 6 at 11:44 AM
$HAE Haemonetics narrows FY25 adjusted EPS view to $4.50-$4.70 from $4.45-$4.75 Consensus $4.59. Narrows FY25 adjusted operating margin to 24% from 23%-24%. Lowers FY25 free cash flow view to $120M-$140M from $130M-$180M.
0 · Reply
DonCorleone77
DonCorleone77 Feb. 6 at 11:43 AM
$HAE Haemonetics reports Q3 adjusted EPS $1.19, consensus $1.17 Reports Q3 revenue $348.5M, consensus $352.88M. Chris Simon, Haemonetics' CEO, stated: "Our record third-quarter margins demonstrate our long-range plan is successfully driving profitable growth. We are gaining share, driving meaningful value through our differentiated technologies and strengthening our leadership as we navigate external market challenges, while accelerating portfolio evolution for further margin expansion. We are confident in the foundation we are building for sustained long-term growth across our business."
0 · Reply